{"id":"NCT00618956","sponsor":"Forest Laboratories","briefTitle":"A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-07","completion":null,"firstPosted":"2008-02-20","resultsPosted":"2009-09-03","lastUpdate":"2009-11-20"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Milnacipran hydrochloride","otherNames":["Ixel (outside of United States)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.","primaryOutcome":{"measure":"Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4","timeFrame":"4 weeks (1 week of dose-escalation, 3 weeks of 100 mg/d)","effectByArm":[{"arm":"Placebo","deltaMin":-0.9,"sd":1},{"arm":"Milnacipran","deltaMin":4,"sd":0.8}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["24188161"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":111},"commonTop":["Nausea","Headache","Constipation","Tachycardia","Insomnia"]}}